Cargando…

Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy

Despite combination chemotherapy demonstrating a positive effect on survival, the clinical outcomes of pancreatic adenocarcinoma (PDAC) remain poor. Radiotherapy was previously a component of the curative treatment of PDAC. Advances in imaging and computer sciences have enabled the prescription of h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jan, I-Shiow, Ch’ang, Hui Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439654/ https://www.ncbi.nlm.nih.gov/pubmed/37596627 http://dx.doi.org/10.1186/s13014-023-02328-y

Ejemplares similares

Krüppel-like Factor 10 as a Prognostic and Predictive Biomarker of Radiotherapy in Pancreatic Adenocarcinoma
por: Tsai, Yi-Chih, et al.
Publicado: (2023)

Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases
por: Shi, Si, et al.
Publicado: (2018)

Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma
por: Ng, Sylvia S. W., et al.
Publicado: (2022)

Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)

Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy
por: Chang, Xiao, et al.
Publicado: (2021)

Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?
por: Rosumeck, Nathalie, et al.
Publicado: (2021)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency
por: Tsai, Yi-Chih, et al.
Publicado: (2021)

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials
por: Ejlsmark, Mathilde Weisz, et al.
Publicado: (2023)

Radiotherapy for stage IIA rectal cancer may not benefit all
por: Hu, Xiang, et al.
Publicado: (2017)

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study
por: Garnier, Jonathan, et al.
Publicado: (2020)

Early or delayed radiotherapy after prostatectomy—who really benefits?
por: van der Poel, Henk, et al.
Publicado: (2017)

Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review
por: Buwenge, Milly, et al.
Publicado: (2022)

Krüppel-like factor 10 modulates stem cell phenotypes of pancreatic adenocarcinoma by transcriptionally regulating notch receptors
por: Tsai, Yi-Chih, et al.
Publicado: (2023)

Chemoradiation After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma is it of Proven Benefit?
por: Garden, O. J.
Publicado: (1999)

Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis
por: Kim, Se Ik, et al.
Publicado: (2019)

Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy
por: Xu, Bin, et al.
Publicado: (2023)

Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elderly patients
por: Kim, Carolyn H, et al.
Publicado: (2013)

The Effects of Radiotherapy on Pancreatic Ductal Adenocarcinoma in Patients with Liver Metastases
por: Wu, Linxia, et al.
Publicado: (2022)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Fatty Pancreas-Centered Metabolic Basis of Pancreatic Adenocarcinoma: From Obesity, Diabetes and Pancreatitis to Oncogenesis
por: Chang, Ming-Ling
Publicado: (2022)

Who benefits from diagnostic labels for developmental disorders?
por: Werkhoven, Sander, et al.
Publicado: (2022)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Identification of children who may benefit from self-hypnosis at a pediatric pulmonary center
por: Anbar, Ran D, et al.
Publicado: (2005)

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment
por: Winters, Nicholas, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Is there any benefit to particles over photon radiotherapy?
por: Goossens, Maria E, et al.
Publicado: (2019)

Predictive dosimetric parameters for gastrointestinal toxicity with hypofractioned radiotherapy in pancreatic adenocarcinoma
por: Liu, Xian, et al.
Publicado: (2016)

Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series
por: Zhao, Li, et al.
Publicado: (2022)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
por: Biagi, James J., et al.
Publicado: (2023)

The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis
por: Chang, Jeffrey S., et al.
Publicado: (2018)

Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
por: Chang, John C., et al.
Publicado: (2017)

Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma
por: Maximous, Doaa W, et al.
Publicado: (2009)

Is Laparoscopic Pancreaticoduodenectomy Feasible for Pancreatic Ductal Adenocarcinoma?
por: Kang, Chang Moo, et al.
Publicado: (2020)

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
por: Park, Hyung, et al.
Publicado: (2022)

Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy
por: Cho, Won Kyung, et al.
Publicado: (2022)

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
por: Chang, Hsuen-Wen, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy
por: Du, Xiao-Jing, et al.
Publicado: (2015)

New machine learning model predicts who may benefit most from COVID-19 vaccination
por: Wedlund, Leia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gbgg4geul3f2m3obgpdl9mrbhe